866-997-4948(US-Canada Toll Free)

Germ Cell Tumors - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 48 Pages


Global Markets Directs, \'Germ Cell Tumors Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Germ Cell Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Germ Cell Tumors. Germ Cell Tumors Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Germ Cell Tumors.
  • A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Germ Cell Tumors pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Germ Cell Tumors.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Germ Cell Tumors pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Germ Cell Tumors Overview 6
Therapeutics Development 7
Pipeline Products for Germ Cell Tumors - Overview 7
Pipeline Products for Germ Cell Tumors - Comparative Analysis 8
Germ Cell Tumors - Therapeutics under Development by Companies 9
Germ Cell Tumors - Therapeutics under Investigation by Universities/Institutes 10
Germ Cell Tumors - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Germ Cell Tumors - Products under Development by Companies 13
Germ Cell Tumors - Products under Investigation by Universities/Institutes 14
Germ Cell Tumors - Companies Involved in Therapeutics Development 15
ZIOPHARM Oncology, Inc. 15
ArQule, Inc. 16
Tolero Pharmaceuticals, Inc. 17
Germ Cell Tumors - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Assessment by Therapeutic Class 28
Drug Profiles 30
alvocidib hydrocholride - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
palifosfamide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
tivantinib - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Allogeneic Tumor Cell Vaccine + [celecoxib] + [cyclophosphamide] - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Combretastatin Analogs - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Germ Cell Tumors - Recent Pipeline Updates 38
Germ Cell Tumors - Dormant Projects 44
Germ Cell Tumors - Product Development Milestones 45
Featured News & Press Releases 45
Nov 14, 2011: ZIOPHARM Oncology Announces Promising Data From Phase Ib Study Of Palifosfamide In Small Cell Lung And Other Cancers At AACR-NCI-EORTC Meeting 45
May 31, 2008: Amgen Announces Interim Phase 2 Results Of Denosumab In Cell Tumor of Bone 45

Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Table


Number of Products under Development for Germ Cell Tumors, H2 2013 7
Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
Germ Cell Tumors - Pipeline by ZIOPHARM Oncology, Inc., H2 2013 15
Germ Cell Tumors - Pipeline by ArQule, Inc., H2 2013 16
Germ Cell Tumors - Pipeline by Tolero Pharmaceuticals, Inc., H2 2013 17
Assessment by Monotherapy Products, H2 2013 18
Assessment by Combination Products, H2 2013 19
Number of Products by Stage and Target, H2 2013 21
Number of Products by Stage and Mechanism of Action, H2 2013 23
Number of Products by Stage and Route of Administration, H2 2013 25
Number of Products by Stage and Molecule Type, H2 2013 27
Number of Products by Stage and Therapeutic Class, H2 2013 29
Germ Cell Tumors Therapeutics - Recent Pipeline Updates, H2 2013 38
Germ Cell Tumors - Dormant Projects, H2 2013 44

List of Chart


Number of Products under Development for Germ Cell Tumors, H2 2013 7
Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H2 2013 8
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Top 10 Target, H2 2013 20
Number of Products by Stage and Top 10 Target, H2 2013 21
Number of Products by Top 10 Mechanism of Action, H2 2013 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 23
Number of Products by Top 10 Route of Administration, H2 2013 24
Number of Products by Stage and Top 10 Route of Administration, H2 2013 25
Number of Products by Top 10 Molecule Type, H2 2013 26
Number of Products by Stage and Top 10 Molecule Type, H2 2013 27
Number of Products by Top 10 Therapeutic Class, H2 2013 28
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *